+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Malignant Mesothelioma Therapeutics Market 2019-2023 - Product Image

Global Malignant Mesothelioma Therapeutics Market 2019-2023

  • ID: 4804037
  • Report
  • July 2019
  • Region: Global
  • 125 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli LillyCo.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • MORE
Global Malignant Mesothelioma Therapeutics Market: About this market

A malignant mesothelioma is a rare form of cancer affecting the thin tissue known as mesothelium that lines the lung, chest wall, and abdomen. The malignant mesothelioma therapeutics market analysis considers sales from both chemotherapy and other therapeutics. This analysis also considers the sales of malignant mesothelioma therapeutics in Asia, Europe, North America, and ROW. In 2018, the chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing demand for chemotherapy will play a significant role in the chemotherapy segment to maintain its market position. Also, our global malignant mesothelioma therapeutics report also looks at factors such as increasing adoption of combination therapies, increasing use of asbestos for commercial purposes, and special regulatory designations. However, a long latency period of malignant mesothelioma, lack of disease-specific biomarkers in earlier stages, and development and approval of advanced devices for cancer treatment may hamper the growth of the malignant mesothelioma therapeutics industry over the forecast period.

Global Malignant Mesothelioma Therapeutics Market: Overview

Increasing the use of asbestos for commercial purposes

Exposure to asbestos is the primary risk factor for malignant mesothelioma. The significant rise in the use of asbestos in commercial purposes such as building materials, machines, and transport vehicles is causing this disease in the workers due to regular exposure. The extensive use of asbestos for commercial purpose will lead to the expansion of the global malignant mesothelioma therapeutics market at a CAGR of almost 7% during the forecast period.

Increasing awareness of malignant mesothelioma

The increasing incidence and prevalence of malignant mesothelioma across the world leading to an increasing need for awareness initiatives to diagnose and treat the disease at earlier stages. Many organizations are spreading awareness about the disease and advising workers who are regularly exposed to asbestos to undergo regular screening of malignant mesothelioma, which may prevent the disease progression to advanced stages. This increasing awareness is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global malignant mesothelioma therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global malignant mesothelioma therapeutics market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading malignant mesothelioma therapeutics companies, that include Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Pfizer Inc.

Also, the malignant mesothelioma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli LillyCo.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Chemotherapy - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing awareness of malignant mesothelioma
  • Development of novel therapies
  • Reimbursement policies for chemotherapy
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 21: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Other therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in North America
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in Europe
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Asia
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Drug designations
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 49: Bristol-Myers Squibb Co. - Product segments
Exhibit 50: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 51: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 52: Bristol-Myers Squibb Co. - Key offerings
Exhibit 53: Bristol-Myers Squibb Co. - Key customers
Exhibit 54: Eli Lilly and Co. - Vendor overview
Exhibit 55: Eli Lilly and Co. - Business segments
Exhibit 56: Eli Lilly and Co. - Organizational developments
Exhibit 57: Eli Lilly and Co. - Geographic focus
Exhibit 58: Eli Lilly and Co. - Segment focus
Exhibit 59: Eli Lilly and Co. - Key offerings
Exhibit 60: Eli Lilly and Co. - Key customers
Exhibit 61: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 63: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 64: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 66: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 67: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 68: Merck & Co. Inc. - Vendor overview
Exhibit 69: Merck & Co. Inc. - Business segments
Exhibit 70: Merck & Co. Inc. - Organizational developments
Exhibit 71: Merck & Co. Inc. - Geographic focus
Exhibit 72: Merck & Co. Inc. - Segment focus
Exhibit 73: Merck & Co. Inc. - Key offerings
Exhibit 74: Merck & Co. Inc. - Key customers
Exhibit 75: Pfizer Inc. - Vendor overview
Exhibit 76: Pfizer Inc. - Business segments
Exhibit 77: Pfizer Inc. - Organizational developments
Exhibit 78: Pfizer Inc. - Geographic focus
Exhibit 79: Pfizer Inc. - Segment focus
Exhibit 80: Pfizer Inc. - Key offerings
Exhibit 81: Pfizer Inc. - Key customers
Exhibit 82: Validation techniques employed for market sizing
Exhibit 83: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Eli LillyCo.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global malignant mesothelioma therapeutics market: Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing awareness of malignant mesothelioma”

According to the report, one of the major drivers for this market is the increasing use of asbestos for commercial purposes.

Further, the report states that one of the major factors hindering the growth of this market is the long latency period of malignant mesothelioma.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bristol-Myers Squibb Co.
  • Eli LillyCo.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll